ArticleCellular and molecular neurobiology2021
The Interplay of Tau Protein and β-Amyloid: While Tauopathy Spreads More Profoundly Than Amyloidopathy, Both Processes Are Almost Equally Pathogenic.
Article in Cellular and molecular neurobiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 17 citations in OpenAlex.
- Improving effects of melatonin on memory and synaptic potentiation in a mouse model of Alzheimer's-like disease: the involvement of glutamate homeostasis and mGluRs receptors.Behavioral and brain functions : BBF · 2025Article
- Iron accumulation/overload and Alzheimer's disease risk factors in the precuneus region: A comprehensive narrative review.Aging medicine (Milton (N.S.W)) · 2024Review
- The psychiatric symptoms in anti-IgLON5 disease: Case report and literature review.Clinical case reports · 2024Article
- Intra-hippocampal cis-P tau microinjection induces long-term changes in behavior and synaptic plasticity in mice.Behavioral and brain functions : BBF · 2023Article
- Tau Aggregation Inhibiting Peptides as Potential Therapeutics for Alzheimer Disease.Cellular and molecular neurobiology · 2023Review
- Earlier Detection of Alzheimer's Disease Based on a Novel BiomarkerBiosensors · 2022Article
- Quantitative susceptibility mapping as an imaging biomarker for Alzheimer's disease: The expectations and limitations.Frontiers in neuroscience · 2022Review
Corrections and comments
- Retraction · 2024-03-21Author Unresponsive · Concerns/Issues about Data · Concerns/Issues about Image · Duplication of Data · Duplication of/in Image · Euphemisms for Duplication · Objections by Author(s) · Unreliable Data · · See also: https://pubpeer.com/publications/99D2D27813298FF4353C4A02CCE859
- Retracted
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
Alzheimer's disease (AD) is a neurodegenerative disorder, in which amyloid precursor protein (APP) misprocessing and tau protein hyperphosphorylation are well-established pathogenic cascades. Despite extensive considerations, the central mediator of neuronal cell death upon AD remains under debate. Therefore, we examined the direct interplay between tauopathy and amyloidopathy processes. We employed primary culture neurons and examined pathogenic P-tau and Aβ oligomers upon hypoxia treatment by immunofluorescence and immunoblotting. We observed both tauopathy and amyloidopathy processes upon the hypoxia condition. We also applied Aβ
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.